Integrated Advisors Network LLC Lowers Stock Position in Axon Enterprise, Inc $AXON

Integrated Advisors Network LLC lessened its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 70.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,338 shares of the biotechnology company’s stock after selling 3,258 shares during the period. Integrated Advisors Network LLC’s holdings in Axon Enterprise were worth $960,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. NEOS Investment Management LLC lifted its stake in shares of Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after purchasing an additional 11,482 shares during the period. Vanguard Group Inc. grew its position in Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after buying an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after buying an additional 5,953 shares in the last quarter. BIT Capital GmbH lifted its position in shares of Axon Enterprise by 75.6% during the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after acquiring an additional 1,522 shares during the period. Finally, Wealthedge Investment Advisors LLC boosted its stake in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after acquiring an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In other news, CFO Brittany Bagley sold 2,000 shares of Axon Enterprise stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the transaction, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. The trade was a 1.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey C. Kunins sold 1,797 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total transaction of $968,996.31. Following the sale, the insider directly owned 83,485 shares of the company’s stock, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 58,040 shares of company stock worth $32,251,738. Company insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley lowered their target price on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. UBS Group dropped their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Needham & Company LLC cut their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Finally, William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $542.40 on Monday. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The company has a market capitalization of $43.61 billion, a price-to-earnings ratio of 356.84, a price-to-earnings-growth ratio of 12.23 and a beta of 1.46. The firm’s fifty day moving average price is $537.92 and its 200 day moving average price is $623.54.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the previous year, the firm earned $2.08 EPS. The company’s revenue was up 38.5% on a year-over-year basis. On average, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.